A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)

Trial Profile

A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Aug 2015 Ono Pharmaceutical obtained the approval for partial changes in the manufacturing and marketing authorization of transdermal patch therapy RIVASTACH PATCH to treat mild-to-moderate Alzheimer-type dementia to add "dosage and administration", in which the dose is increased to the maintenance dose by one step.
    • 21 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
    • 28 Jan 2014 Actual number of patients changed from 79 to 101, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top